Kura Oncology says Blood paper shows 87% response rate for ziftomenib plus venetoclax/azacitidine in relapsed NPM1-mutated AML

Kura Oncology, Inc.

Kura Oncology, Inc.

KURA

0.00
  • Kura Oncology flagged a Blood publication of updated KOMET-007 Phase 1a/b results for ziftomenib with venetoclax, azacitidine in relapsed or refractory NPM1-mutated AML.
  • Results were presented as updated, more mature data in the journal publication, not as a future conference readout.
  • The triplet regimen delivered meaningful remissions, with deeper, more durable responses in venetoclax-naïve patients than in venetoclax-experienced patients.
  • Safety looked manageable, with low rates of key treatment-limiting events, supporting continued development of ziftomenib-based combinations.
  • Ziftomenib is already marketed in the US as monotherapy for certain relapsed or refractory NPM1-mutated AML patients; the combination remains investigational.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.